BriaCell Presents Clinical Data at 2026 ASCO Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2026
0mins
BriaCell Therapeutics announces clinical data from three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting, taking place May 29-June 2, 2026 at McCormick Place, Chicago, Illinois. The presentations will include two poster presentations featuring data from BriaCell's ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, Bria-ABC, and one poster highlighting further analyses of Phase 2 data. Key highlights: Final Phase 2 Bria-IMT median overall survival is 16.6 months; Positive Quality of Life data from the ongoing Phase 3 study in heavily pre-treated metastatic breast cancer patients; Biomarker analyses from the ongoing Phase 3 study confirm predictors of anti-cancer response seen in Phase 2
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCTX
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BriaCell Engages CRA and Kaleio for Market Access Evaluation of Bria-IMT
- Market Evaluation Partnership: BriaCell Therapeutics has engaged Charles River Associates and Kaleio, Inc. to assess the pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer, thereby supporting brand strategies and commercial readiness solutions.
- Clinical Trial Progress: Bria-IMT is currently undergoing a pivotal Phase 3 clinical study (ClinicalTrials.gov identifier: NCT06072612), and while it is not yet commercially approved, the success of this study could pave the way for future market access.
- Commercial Readiness Steps: This collaboration is viewed as a prudent step by BriaCell as it continues to evaluate Bria-IMT and prepares for potential commercialization planning and strategic discussions, reflecting the company's focus on future market opportunities.
- Innovative Treatment Development: BriaCell is dedicated to developing novel immunotherapies to transform cancer care, and as Bria-IMT progresses through clinical trials, the company's competitive position and industry impact are expected to significantly enhance.
See More
BriaCell Partners with Uneedle for Microneedle Technology in Cancer Treatment
- Partnership Agreement: BriaCell Therapeutics has signed a Memorandum of Understanding with Uneedle, a Netherlands-based company, to support the commercial readiness of its microneedle technology for Bria-IMT, ensuring scalable production contingent on regulatory approval, which could provide a more convenient treatment option for breast cancer patients.
- Current Technology Use: Uneedle's microneedle system is already being utilized in BriaCell's pivotal Phase 3 study evaluating Bria-IMT for advanced metastatic breast cancer, highlighting the technology's significance and potential in clinical applications.
- Enhanced Patient Experience: BriaCell's CEO, William V. Williams, noted that Uneedle's microneedle technology aims to facilitate faster and more convenient drug administration, improving the treatment experience for both patients and providers, which may enhance patient adherence and satisfaction.
- Market Reaction: Despite BCTX closing at $2.97, down 3.57% on Thursday, the stock rebounded to $2.86 in pre-market trading, up 3.70%, indicating a positive market response and anticipation of the partnership's future potential.
See More
BriaCell Partners with Uneedle for Microneedle Technology in Cancer Treatment
- MoU Signed: BriaCell has entered into a Memorandum of Understanding with Uneedle to support the commercial readiness of Bria-IMT, utilizing Uneedle's microneedle technology for intradermal administration to enhance treatment outcomes.
- Clinical Trial Application: Uneedle's microneedle technology is currently being utilized in BriaCell's pivotal Phase 3 study, aimed at providing faster and more convenient drug administration for patients with advanced metastatic breast cancer, thereby improving the experience for both patients and providers.
- Commercial Potential: The MoU reflects the ongoing commitment of both parties to the regulatory and commercial development of Bria-IMT, with plans to detail the scaling of Uneedle's microneedle devices for commercial use, which could accelerate market entry upon regulatory approval.
- Technological Advantage: BriaCell's CEO William V. Williams noted that Uneedle's microneedle technology enhances the efficiency and reliability of drug delivery, which is expected to provide a more patient-friendly treatment experience, further strengthening the company's competitive position in the biotechnology sector.
See More
BriaCell Reports Promising Phase 2 Data for Breast Cancer Treatment
- Survival Rate Improvement: The Bria-IMT regimen demonstrated a 55% one-year and 27% two-year survival rate in heavily pre-treated metastatic breast cancer patients, indicating significant potential for improving survival, particularly in patients who have failed multiple therapies.
- Clinical Data Validation: At the 2026 ASCO Annual Meeting, BriaCell reported a median overall survival of 16.6 months in Phase 2 studies, with a clinical benefit rate of 62% among patients who had undergone various treatments, underscoring the regimen's efficacy and tolerability.
- Biomarker Insights: Ongoing biomarker analyses from the Phase 3 study further validate potential predictors of anti-cancer response, with DTH-positive patients showing a median survival of 11.9 months, highlighting the importance of biomarkers in predicting treatment effectiveness.
- Quality of Life Enhancement: In the Bria-ABC study, heavily pre-treated patients maintained stable quality of life without significant toxicity, supporting the feasibility of the regimen in clinical settings and suggesting potential for home self-administration.
See More
BriaCell Therapeutics Prices 1.4 Million Share Best-Efforts Offering
- Offering Size: BriaCell Therapeutics announced a best-efforts offering of approximately 1.4 million shares, indicating the company's strategy to raise capital in the market.
- Market Reaction: The specific pricing details of the offering have not been disclosed, which may affect investor confidence in the company's future fundraising capabilities.
- Use of Proceeds: While the use of proceeds has not been detailed, such financing is typically aimed at research and operational expenses, potentially impacting the company's future project timelines.
- Investor Attention: Investors should monitor subsequent market reactions and company announcements to assess the potential impact of this offering on stock price and financial health.
See More
BriaCell Therapeutics Prices Public Offering at $3.25 per Share
- Public Offering Pricing: BriaCell Therapeutics Corp. has priced its public offering at $3.25 per share for 1.45 million shares, expecting total gross proceeds of approximately $4.7 million, indicating a proactive approach to financing.
- Clear Use of Proceeds: The company intends to utilize the net proceeds for working capital requirements, general corporate purposes, and advancing its business objectives, reflecting a strategic plan for future growth.
- Market Performance Volatility: Over the past year, BCTX's stock has traded between $2.98 and $36.90; despite closing last Friday up 1.68% at $3.64, it fell 12.64% to $3.18 in the overnight market, highlighting the stock's sensitivity to market fluctuations.
- Underwriter's Role: ThinkEquity is acting as the sole placement agent for the offering, underscoring its significant role in the capital markets and potentially influencing investor confidence in the stock.
See More
BriaCell Engages CRA and Kaleio for Market Access Evaluation of Bria-IMT
- Market Evaluation Partnership: BriaCell Therapeutics has engaged Charles River Associates and Kaleio, Inc. to assess the pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer, thereby supporting brand strategies and commercial readiness solutions.
- Clinical Trial Progress: Bria-IMT is currently undergoing a pivotal Phase 3 clinical study (ClinicalTrials.gov identifier: NCT06072612), and while it is not yet commercially approved, the success of this study could pave the way for future market access.
- Commercial Readiness Steps: This collaboration is viewed as a prudent step by BriaCell as it continues to evaluate Bria-IMT and prepares for potential commercialization planning and strategic discussions, reflecting the company's focus on future market opportunities.
- Innovative Treatment Development: BriaCell is dedicated to developing novel immunotherapies to transform cancer care, and as Bria-IMT progresses through clinical trials, the company's competitive position and industry impact are expected to significantly enhance.
See More
BriaCell Partners with Uneedle for Microneedle Technology in Cancer Treatment
- Partnership Agreement: BriaCell Therapeutics has signed a Memorandum of Understanding with Uneedle, a Netherlands-based company, to support the commercial readiness of its microneedle technology for Bria-IMT, ensuring scalable production contingent on regulatory approval, which could provide a more convenient treatment option for breast cancer patients.
- Current Technology Use: Uneedle's microneedle system is already being utilized in BriaCell's pivotal Phase 3 study evaluating Bria-IMT for advanced metastatic breast cancer, highlighting the technology's significance and potential in clinical applications.
- Enhanced Patient Experience: BriaCell's CEO, William V. Williams, noted that Uneedle's microneedle technology aims to facilitate faster and more convenient drug administration, improving the treatment experience for both patients and providers, which may enhance patient adherence and satisfaction.
- Market Reaction: Despite BCTX closing at $2.97, down 3.57% on Thursday, the stock rebounded to $2.86 in pre-market trading, up 3.70%, indicating a positive market response and anticipation of the partnership's future potential.
See More
BriaCell Partners with Uneedle for Microneedle Technology in Cancer Treatment
- MoU Signed: BriaCell has entered into a Memorandum of Understanding with Uneedle to support the commercial readiness of Bria-IMT, utilizing Uneedle's microneedle technology for intradermal administration to enhance treatment outcomes.
- Clinical Trial Application: Uneedle's microneedle technology is currently being utilized in BriaCell's pivotal Phase 3 study, aimed at providing faster and more convenient drug administration for patients with advanced metastatic breast cancer, thereby improving the experience for both patients and providers.
- Commercial Potential: The MoU reflects the ongoing commitment of both parties to the regulatory and commercial development of Bria-IMT, with plans to detail the scaling of Uneedle's microneedle devices for commercial use, which could accelerate market entry upon regulatory approval.
- Technological Advantage: BriaCell's CEO William V. Williams noted that Uneedle's microneedle technology enhances the efficiency and reliability of drug delivery, which is expected to provide a more patient-friendly treatment experience, further strengthening the company's competitive position in the biotechnology sector.
See More
BriaCell Reports Promising Phase 2 Data for Breast Cancer Treatment
- Survival Rate Improvement: The Bria-IMT regimen demonstrated a 55% one-year and 27% two-year survival rate in heavily pre-treated metastatic breast cancer patients, indicating significant potential for improving survival, particularly in patients who have failed multiple therapies.
- Clinical Data Validation: At the 2026 ASCO Annual Meeting, BriaCell reported a median overall survival of 16.6 months in Phase 2 studies, with a clinical benefit rate of 62% among patients who had undergone various treatments, underscoring the regimen's efficacy and tolerability.
- Biomarker Insights: Ongoing biomarker analyses from the Phase 3 study further validate potential predictors of anti-cancer response, with DTH-positive patients showing a median survival of 11.9 months, highlighting the importance of biomarkers in predicting treatment effectiveness.
- Quality of Life Enhancement: In the Bria-ABC study, heavily pre-treated patients maintained stable quality of life without significant toxicity, supporting the feasibility of the regimen in clinical settings and suggesting potential for home self-administration.
See More
BriaCell Therapeutics Prices 1.4 Million Share Best-Efforts Offering
- Offering Size: BriaCell Therapeutics announced a best-efforts offering of approximately 1.4 million shares, indicating the company's strategy to raise capital in the market.
- Market Reaction: The specific pricing details of the offering have not been disclosed, which may affect investor confidence in the company's future fundraising capabilities.
- Use of Proceeds: While the use of proceeds has not been detailed, such financing is typically aimed at research and operational expenses, potentially impacting the company's future project timelines.
- Investor Attention: Investors should monitor subsequent market reactions and company announcements to assess the potential impact of this offering on stock price and financial health.
See More
BriaCell Therapeutics Prices Public Offering at $3.25 per Share
- Public Offering Pricing: BriaCell Therapeutics Corp. has priced its public offering at $3.25 per share for 1.45 million shares, expecting total gross proceeds of approximately $4.7 million, indicating a proactive approach to financing.
- Clear Use of Proceeds: The company intends to utilize the net proceeds for working capital requirements, general corporate purposes, and advancing its business objectives, reflecting a strategic plan for future growth.
- Market Performance Volatility: Over the past year, BCTX's stock has traded between $2.98 and $36.90; despite closing last Friday up 1.68% at $3.64, it fell 12.64% to $3.18 in the overnight market, highlighting the stock's sensitivity to market fluctuations.
- Underwriter's Role: ThinkEquity is acting as the sole placement agent for the offering, underscoring its significant role in the capital markets and potentially influencing investor confidence in the stock.
See More
